To discover new cardiac biomarkers Mirnext uses high-throughput systems in a disease-oriented strategy. This approach proved successful and yielded miR423-5p as clinically meaningful biomarker for heart failure.

Mirnext has a strong focus on the identification of novel biomarkers for cardiovascular diseases. The company has identified both protein and miRNA biomarkers that can be used for diagnosis and prognosis of patients with heart failure and coronary artery disease. In a next phase these biomarkers are validated in large patient cohorts with different disease phenotypes. Mirnext is continuously expanding its portfolio by performing innovative discovery approaches to identify novel and clinically meaningful biomarkers.

Bookmark and Share